CSL689: Clinical Trials

1 trial of CSL689, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1
Phase 31Terminated 1

Follow CSL689: new trials by email Literature Review of CSL689 trials Research Report on CSL689

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
CSL689, Eptacog alfa (activated) - Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Phase 2 / Phase 3TerminatedCSL Behring252015-07-232019-08-28

Sponsors

CSL Behring (1)

Countries

Georgia (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Russia (1)  ·  South Africa (1)  ·  Spain (1)  ·  Thailand (1)  ·  Ukraine (1)  ·  United Kingdom (1)